Advancements in the Management of Rotator Cuff (RC) Tears

Introduction

• Miller's Review of Orthopaedics, 9th Ed.
• Firestein & Kelley's Textbook of Rheumatology, 2-Vol Set

I. Non-Operative (Conservative) Management

• Asymptomatic full-thickness tears
• Elderly patients (>65 years)
• Patients with medical contraindications to surgery
• Rotator cuff arthropathy

Components:

1. Activity modification - Avoidance of repeated forward flexion beyond 90 degrees
2. NSAIDs - Pain control; patients on long-term NSAIDs require monitoring for GI, hepatic, and renal toxicity
3. Physiotherapy (3 phases):
   • Phase 1: Restore motion - pendulum exercises, wand-assisted passive motion, overhead pulleys, posterior capsular stretching
   • Phase 2: Strengthening - elastic surgical tubing, rotator cuff and deltoid strengthening
   • Phase 3: Return to function and overhead activity
4. Subacromial corticosteroid injections - Repeated every 3 months if needed; avoid injection into the tendon itself; should be stopped at least 6 months before planned surgical repair to reduce failure rates
5. Ultrasound therapy, heat pre-exercise, ice post-activity, deep massage

• Firestein & Kelley's Textbook of Rheumatology, p. 893

II. Evolution of Surgical Techniques

1. Open Repair (Historical)

2. Mini-Open (Deltoid-Sparing) Repair

3. All-Arthroscopic Repair (Current Standard)

• Visualisation of the glenohumeral joint and associated pathology (labral tears, biceps tendon pathology)
• Less soft tissue damage, less post-operative pain
• Faster rehabilitation
• Equivalent or superior outcomes compared to open repair

"The operative approach has evolved from a classic open approach to a 'mini-open' or deltoid-sparing approach and now to an all-arthroscopic technique." - Miller's Review of Orthopaedics, 9th Ed., p. 391

III. Fixation Technique Advancements

Single-Row Repair

Double-Row Repair

• Greater footprint contact area
• Improved biomechanical strength in vitro

Suture-Bridge (Transosseous-Equivalent) Technique

"Surgical techniques have evolved to include double-row and suture-bridge fixation techniques, which have improved biomechanical strength in vitro; clinical correlation remains controversial." - Miller's Review of Orthopaedics, 9th Ed.

IV. Management of Large and Massive Tears

• Acromiohumeral distance <7 mm on AP radiograph (suggesting irreparability)
• Fatty infiltration >50% of muscle belly
• Tear retracted to glenoid level
• Tangent sign positive on MRI (supraspinatus belly fails to cross the coracoid-scapular spine line)

Options for Irreparable Tears:

• Provides good pain relief in elderly patients
• Does not restore strength
• Useful as a palliative procedure

• A well-balanced partial repair has been shown to be comparable to total repair in selected cases
• Biceps tenotomy/tenodesis added when pain is the dominant symptom

• Latissimus dorsi transfer to the greater tuberosity: for younger patients (<65 years) with massive posterosuperior tears, no glenohumeral arthritis, and significant fatty atrophy
• Lower trapezius transfer: emerging technique, especially combined with superior capsular reconstruction for posterosuperior tears
• Pectoralis major transfer: for subscapularis-deficient shoulders (places the musculocutaneous nerve at risk)

• Popularised by Mihata (2012) in Japan
• A graft (fascia lata autograft or dermal allograft) is interposed between the superior glenoid and greater tuberosity to restore superior stability and reduce subacromial contact pressure
• Prevents superior humeral head migration in irreparable tears
• Growing clinical enthusiasm, though rigorous long-term outcome data are still accumulating
• Recent studies (2023-2024) show benefit when combined with lower trapezius transfer for posterosuperior massive tears

"There has been enthusiasm for a procedure termed 'superior capsular reconstruction' using either fascia lata autograft or allograft; rigorous clinical outcome studies are still lacking." - Miller's Review of Orthopaedics, 9th Ed.

• An absorbable balloon inserted into the subacromial space arthroscopically and inflated with saline
• Mechanically reduces superior migration of the humeral head
• Acts as a spacer in massive irreparable tears
• A 2024 systematic review and meta-analysis (PMID: 38922784) found that patient selection and physical therapy protocols are key determinants of outcome
• Absorbed over approximately 12 months; intended as a bridge or standalone palliative option

• A 2024 systematic review (PMID: 39254725) confirmed that LHB autograft is effective in managing large-to-massive RC tears
• The biceps tendon is detached and used to augment or bridge the tear
• Combined biceps augmentation reduces retear rates compared to repair without augmentation

V. Reverse Total Shoulder Arthroplasty (RTSA)

• Reverses the normal ball-and-socket geometry: the glenoid becomes convex (ball) and the humeral component becomes concave (socket)
• Shifts the center of rotation medially and inferiorly, increasing the deltoid lever arm
• The deltoid muscle compensates for the absent rotator cuff, allowing near-normal elevation
• Primary indications: irreparable RC tear with pseudoparalysis, RC tear arthropathy (Hamada grading), or failed previous repair in the elderly

"Reverse total shoulder replacement...reverses the normal relationship between scapular and humeral components, moving the center of rotation medially and distally to increase the lever arm length of the deltoid muscle." - Firestein & Kelley's Textbook of Rheumatology, p. 893

• Age >65 years
• Pseudoparalysis + glenohumeral arthritis
• Poor prognostic factors for biological healing (fatty atrophy, diabetes, smoking)

VI. Biologic Augmentation - The Emerging Frontier

1. Platelet-Rich Plasma (PRP)

• Derived from autologous blood by centrifugation; provides concentrated growth factors (PDGF, TGF-β, VEGF, IGF-1)
• Applied at the tendon-bone interface during arthroscopic repair
• 2024 meta-analyses suggest PRP reduces retear rates in small-to-medium tears and improves structural healing on imaging
• Results in nonoperative settings (partial tears, tendinopathy) show modest improvement in pain and function
• Limitation: heterogeneity in PRP preparations (leukocyte-rich vs. leukocyte-poor, platelet concentration, timing of application) makes comparison across studies difficult

2. Mesenchymal Stem Cells (MSCs) / Bone Marrow Aspirate Concentrate (BMAC)

• MSCs can differentiate into tenocytes and fibrocartilaginous tissue at the enthesis
• BMAC (from iliac crest) provides a concentrated source of MSCs and growth factors
• Early clinical and preclinical studies show improved structural healing and functional scores
• Currently no standardised protocol; regulatory framework varies by jurisdiction

3. Biologic Scaffolds and Augmentation Patches

• Extracellular matrix (ECM) patches (e.g., dermal allograft, porcine small intestinal submucosa): used as bridging or augmentation for massive tears
• Provide structural support and a scaffold for cellular ingrowth
• Xenograft patches have not demonstrated reliable benefit
• Human-derived scaffolds combined with PRP or BMAC show more promise

4. Amniotic Membrane-Derived Products

• Anti-inflammatory and pro-regenerative properties
• Early investigations show potential in partial tears and tendinopathy
• Remains investigational

5. Gene Therapy (Emerging)

• Delivery of growth factor genes (e.g., GDF-5, BMP-2) to the repair site to enhance enthesis regeneration
• Currently pre-clinical; represents a future direction

The AAOS (2026) noted: "Orthobiologics represent a rapidly evolving frontier in the regenerative treatment of rotator cuff tears. Continued high-quality research and standardised protocols will be essential to fully integrate orthobiologics into evidence-based rotator cuff care."

VII. Advances in Diagnosis and Imaging

VIII. Rehabilitation Advances

• Post-operative rehabilitation protocols remain an area of active research
• Current evidence suggests no significant difference in outcomes between early motion and delayed motion protocols, though most surgeons use a 6-week protected phase followed by progressive active range of motion
• Rehabilitation phases post-repair:
  1. Weeks 0-6: Sling immobilisation, passive motion only
  2. Weeks 6-12: Active motion, light strengthening
  3. Months 3+: Progressive strengthening, return to function
• Return to overhead sport: typically 9-12 months

IX. Predictors of Repair Failure

• Age ≥65 years
• Massive tear
• Moderate-severe muscle atrophy on T1 MRI

• 50% fatty infiltration of cuff muscle belly

• Tear retraction to glenoid level
• Diabetes mellitus
• Active smoking
• Poor rehabilitation compliance

X. Algorithmic Approach to Management (Summary)

RC Tear Diagnosed
     |
     |__ Asymptomatic / poor surgical candidate
     |        → Conservative management (activity modification, NSAIDs, PT, injections)
     |
     |__ Symptomatic, failed conservative (>3 months)
              |
              |__ Small-Medium tear → Arthroscopic single/double-row repair
              |
              |__ Large tear → Arthroscopic double-row / suture-bridge repair
              |
              |__ Massive tear - Reparable? 
              |         Yes → Double-row repair ± biologic augmentation
              |         No →
              |              Young patient → Latissimus dorsi transfer / SCR / LHB augmentation
              |              Elderly, no arthritis → Subacromial balloon spacer / debridement
              |              Elderly, RC tear arthropathy → RTSA

Conclusion

• Miller's Review of Orthopaedics, 9th Ed., pp. 390-395
• Firestein & Kelley's Textbook of Rheumatology, pp. 892-893
• Bailey and Love's Short Practice of Surgery, 28th Ed., p. 551
• AAOS Now, March 2026: Orthobiologics in RC Tears
• Sirignano et al. (2024). Subacromial balloon spacer meta-analysis. KSSTA [PMID: 38922784]
• Green et al. (2024). LHB autograft systematic review. Eur J Orthop Surg Traumatol [PMID: 39254725]
• Kelly et al. (2025). Bridging reconstruction vs RTSA meta-analysis. Sports Med Arthrosc Rev [PMID: 40424170]
• Boesel et al. (2025). Large-to-massive RC tear outcomes meta-analysis. Eur J Orthop Surg Traumatol [PMID: 40836122]